Profile http://med.stanford.edu/profiles/Mark_Holodniy/ Email this page Printer friendly version

Key Documents

Mark Holodniy

Professor - Med Center Line, Medicine - Infectious Diseases

Contact Information

Clinical Offices

Infectious Disease 3801 Miranda Ave Ste 132 Palo Alto, CA 94304
Telephone Work (650) 852-3408 Fax (650) 858-3978

Clinical Focus

Infectious Disease
Infectious Diseases

Administrative Appointments

Member, Medical School Faculty Senate , (1999– 2002 )
Member, Administrative Panel on Biosafety , (1995– 2010 )

Honors and Awards

Divisional Award for Exceptional Contributions in Education in the Division of Infectious Disease, Department of Medicine (2004)
Infectious Diseases Teaching Award, Division of Infectious Diseases (2004)
Infectious Diseases Teaching Award, Division of Infectious Diseases (1997)
HIV Program Clinical Excellence Award, Department of Veterans Affairs (2001)

Professional Education

Board Certification: Infectious Disease, American Board of Internal Medicine (1990)
SUMC - Graduate Medical Education (1990) CA
Board Certification: Internal Medicine, American Board of Internal Medicine (1988)
Good Samaritan Regional Medical Center (1988) AZ
Good Samaritan Regional Medical Center (1986) AZ
Northwestern Memorial Hospital (1985) IL
BS, Seattle University Biology (1980)
MD, Northwestern University Medicine (1985)
---, Stanford University Infectious Diseases Fellowship (1990)

Postdoctoral Advisees

Aarthi Chary, Philip Grant, Patricia Schirmer

Graduate & Fellowship Program Affiliations

Community & International Work

Tri-national OPTIMA Trial More »

Current Research Interests

My research program is currently focused in three areas: 1) translational research (HCV/HIV viral evolution and antiviral resistance prevalence and development), 2) HIV/HCV clinical trials (diagnostic assay/medical device, antiretrovirals, ARVs and immunomodulators), and 3) health services research focusing on cost effectiveness of HIV antibody and ARV resistance testing and ARV utilization and clincal outcome.

Clinical Trials

Blood Sample Study of viral and Immune Responses to Treatment in People with HIV or Hepatitis C Infections Recruiting

Publications

Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. Dau B, Ayers D, Singer J, Richard Harrigan P, Brown S, Kyriakides T, William Cameron D, Angus B, Holodniy M. J Acquir Immune Defic Syndr. 2010;
Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. Palacios GC, Sanchez LM, Briones E, Ramirez TJ, Castillo H, Rivera LG, Vazquez CA, Rodriguez-Padilla C, Holodniy M. Int J Infect Dis. 2010; 14 (1): e34-40
Sudden sensorineural hearing loss associated with vardenafil. Snodgrass AJ, Campbell HM, Mace DL, Faria VL, Swanson KM, Holodniy M. Pharmacotherapy. 2010; 30 (1): 112
The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Nosyk B, Sun H, Bansback N, Guh DP, Li X, Barnett P, Bayoumi A, Griffin S, Joyce V, Holodniy M, Owens DK, Anis AH. Qual Life Res. 2009; 18 (7): 815-24
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. Harbecke R, Oxman MN, Arnold BA, Ip C, Johnson GR, Levin MJ, Gelb LD, Schmader KE, Straus SE, Wang H, Wright PF, Pachucki CT, Gershon AA, Arbeit RD, Davis LE, Simberkoff MS, Weinberg A, Williams HM, Cheney C, Petrukhin L, Abraham KG, Shaw A, Manoff S, Antonello JM, Green T, Wang Y, Tan C, Keller PM. J Med Virol. 2009; 81 (7): 1310-22
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST. J Acquir Immune Defic Syndr. 2009; 51 (5): 631-9
Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study. Jamison RL, Shih MC, Humphries DE, Guarino PD, Kaufman JS, Goldfarb DS, Warren SR, Gaziano JM, Lavori P. Am J Kidney Dis. 2009; 53 (5): 779-89
Oseltamivir for treatment and prophylaxis of influenza infection. Schirmer P, Holodniy M. Expert Opin Drug Saf. 2009; 8 (3): 357-71
Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. Lloyd RM, Burns DA, Huong JT, Mathis RL, Winters MA, Tanner M, De La Rosa A, Yen-Lieberman B, Armstrong W, Taege A, McClernon DR, Wetshtein JL, Friedrich BM, Ferguson MR, O'Brien W, Feorino PM, Holodniy M. J Clin Microbiol. 2009; 47 (5): 1491-6
Novel targets for antiretroviral therapy: clinical progress to date. Dau B, Holodniy M. Drugs. 2009; 69 (1): 31-50
Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Raisch DW, Straight TM, Holodniy M. Pharmacotherapy. 2009; 29 (8): 988-92
Infectious complications in OIF/OEF veterans with traumatic brain injury. Dau B, Oda G, Holodniy M. J Rehabil Res Dev. 2009; 46 (6): 673-84
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ. J Infect Dis. 2009; 200 (7): 1068-77
Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease Joyce, V, Barnett PG, Bayoumi A, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W,. Journal of Acquired Immune Deficiency Syndromes. 2009; 50 (1): 27-36
The Relationship Between HIV Infection and Cardiovascular Disease Dau B, Holodniy M. Current Cardiology Reviews. 2008; 4 (3): 203-218
Frequency of HIV screening in the Veterans Health Administration: implications for early diagnosis of HIV infection. Valdiserri RO, Rodriguez F, Holodniy M. AIDS Educ Prev. 2008; 20 (3): 258-64
Cost-effectiveness of HIV screening in patients older than 55 years of age. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Ann Intern Med. 2008; 148 (12): 889-903
Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, Raisch DW, Cunningham F, Lin ET, Olivo N, Deyton LR. Antimicrob Agents Chemother. 2008; 52 (9): 3013-21
HIV infection in the elderly Nguyen N, Holodniy M. Clinical Interventions in Aging. 2008; 3 (4): 1-20
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S. J Interferon Cytokine Res. 2008; 28 (2): 89-100
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A. J Infect Dis. 2008; 197 (6): 825-35
Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Louie JK, Kajon AE, Holodniy M, Guardia-LaBar L, Lee B, Petru AM, Hacker JK, Schnurr DP. Clin Infect Dis. 2008; 46 (3): 421-5
Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. HIV Clin Trials. 2007 Sep-Oct; 8 (5): 293-302
A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E. Med Decis Making. 2007 Nov-Dec; 27 (6): 789-821
Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L. J Acquir Immune Defic Syndr. 2007; 44 (1): 20-9
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Liu Z, Winters M, Holodniy M, Dai H. Angew Chem Int Ed Engl. 2007; 46 (12): 2023-7
Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy. Holodniy M, Drugs. 2007; 67 (18): 2803
HIV testing of at risk patients in a large integrated health care system. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Tempio P, Holodniy M, Sanders GD, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Chavis D, Borowsky LH, Yano EM, Jensen P, Simberkoff MS, Bozzette SA. J Gen Intern Med. 2007; 22 (3): 315-20
Role of Environmental Surveillance in Dtermining the Risk of Hospital-Acquired Legionellosis: A National Surveillance Study With Clinical Correlations Stout, JE, Muder RR, Mietzner S, Wagener MM, Perri MB, DeRoos K, Goodrich D, Arnold W, Williamson T, Ruark O, Treadway C, Eckstein EC, Marshall D, Rafferty ME, Sarro K, Page J, Jenkins R, Oda G, Shimoda KJ, Zervos MJ, Bittner M, Camhi SL, Panwalker AP, Donskey CJ, Nguyen MH, Holodniy M, Yu VL. Infection Control and Hospital Epidemiology. 2007; 28 (7): 818-824
Representational Fluency in HIV Clinical Practice: A Model of Instructor Discourse Banach, MA, Gifford, BR, Holodniy M. Journal of Continuing Education in the Health Professions. 2007; 27 (3): 149-156
Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Sanders GD, Taylor K, VanGroningen R, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Nyland J, Tempio P, Khayr W, Dietzen DJ, Jensen P, Simberkoff MS, Bozzette SA, Holodniy M. Am J Public Health. 2007; 97 (12): 2173-8
Utilization and access to antiretroviral genotypic resistance testing and results within the US Department of Veterans Affairs. Goetz MB, Holodniy M, Poulton JS, Rodriguez FH, Rigsby MO. J Acquir Immune Defic Syndr. 2006; 41 (1): 59-62
Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. Winters MA, Welles SL, Holodniy M. J Virol. 2006; 80 (8): 4196-9
The safety and tolerability of Z-100 in patients infected with HIV-1 Borucki M, Holodniy M, Pierone G, Ruane P, Steinhart C, Williams S, Slom T, Palella F, Hare CB, Yoshida Y, Li KD, Pollard RB. Antiviral Therapy. 2006; 11 297-303
HIV-1 load quantitation: a 17-year perspective. Holodniy M, J Infect Dis. 2006; 194 Suppl 1 S38-44
Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet. Liu M, Holodniy M, Zolopa AR, Shafer RW. MedGenMed. 2006; 8 (1): 24
Prevention of shingles by varicella zoster virus vaccination. Holodniy M, Expert Rev Vaccines. 2006; 5 (4): 431-43
The effect of diagnosis with HIV infection on health-related quality of Life. Honiden S, Sundaram V, Nease RF, Holodniy M, Lazzeroni LC, Zolopa A, Owens DK. Qual Life Res. 2006; 15 (1): 69-82
Proteomic analysis of serum cytokine levels in response to highly active antiretroviral therapy (HAART). Relucio KI, Beernink HT, Chen D, Israelski DM, Kim R, Holodniy M. J Proteome Res. 2005 Mar-Apr; 4 (2): 227-31
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. N Engl J Med. 2005; 352 (6): 570-85
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. N Engl J Med. 2005; 352 (22): 2271-84
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DR. Clin Infect Dis. 2005; 41 (1): 92-9
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. New England Journal of Medicine. 2005; 352 (6): 570-585
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. Terrault, NA, Pawlotsky JM, McHutchison J, Anderson F, Krajden M, Gordon S, Zitron I, Perrillo R, Gish R, Holodniy M, Friesenhahn M.. Journal of Viral Hepatitis. 2005; 12 (5): 465-472
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, Kuramoto K, Ng V, Valdes R, Valsamakis A, Terrault NA. J Clin Microbiol. 2004; 42 (2): 563-9
Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study. Holodniy M, Charlebois ED, Bangsberg DR, Zolopa AR, Schulte M, Moss AR. Int J STD AIDS. 2004; 15 (8): 543-51
Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. Babik JM, Holodniy M. J Virol. 2003; 77 (3): 1940-50
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Chang TL, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, Schoolnik GK, Ho DD, Hillier SL, Holodniy M, Lewicki JA, Lee PP. Proc Natl Acad Sci U S A. 2003; 100 (20): 11672-7
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. AIDS. 2003; 17 (13): 1925-32
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, Holodniy M, Brown ST, Youle M, Gazzard B. Control Clin Trials. 2003; 24 (4): 481-500
Accuracy of the TRUGENE HIV-1 genotyping kit. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd Jr RM, Reid C, Morgan GF, Winslow DL. J Clin Microbiol. 2003; 41 (4): 1586-93
Successful management of disseminated Nocardia transvalensis infection in a heart transplant recipient after development of sulfonamide resistance: case report and review. Lopez FA, Johnson F, Novosad DM, Beaman BL, Holodniy M. J Heart Lung Transplant. 2003; 22 (4): 492-7
Role of Deoxyribonucleoside Kinases and Deoxyribonucleotide Pool Alterations in Nucleoside Reverse Transcriptase Inhibitor Induced Mitochondrial Toxicity Relucio K, Holodniy M. Curr. Med. Chem. - Anti-Infective Agents. 2003; 2 241-262
HIV-1 RNA and viral load. Relucio K, Holodniy M. Clin Lab Med. 2002; 22 (3): 593-610
Multinodular polymyositis in a patient with human immunodeficiency and hepatitis C virus coinfection. Richardson SJ, Lopez F, Rojas S, Cho S, Holodniy M, Herndier B, Katz J. Muscle Nerve. 2001; 24 (3): 433-7
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. Mole L, Schmidgall D, Holodniy M. J Acquir Immune Defic Syndr. 2001; 27 (3): 260-5
Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. Fujinaga M, Schulte M, Holodniy M. Teratology. 2000; 62 (2): 108-14
Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. Holodniy M, Rainen L, Herman S, Yen-Lieberman B. J Clin Microbiol. 2000; 38 (1): 323-6
HIV resistance testing--has it come of age? Holodniy M, AIDS Read. 2000; 10 (8): 474-5
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. AIDS. 2000; 14 (4): 357-66
A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Holodniy M, Koch J, Mistal M, Schmidt JM, Khandwala A, Pennington JE, Porter SB. Am J Gastroenterol. 1999; 94 (11): 3267-73
Viral Load Monitoring in HIV Infection. Holodniy M, Curr Infect Dis Rep. 1999; 1 (5): 497-503
Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Mole L, Ockrim K, Holodniy M. Pharmacoeconomics. 1999; 16 (3): 307-15
Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. Niu MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM. J Infect Dis. 1998; 178 (1): 80-91
Human immunodeficiency virus type 1 populations in blood and semen. Delwart EL, Mullins JI, Gupta P, Learn GH, Holodniy M, Katzenstein D, Walker BD, Singh MK. J Virol. 1998; 72 (1): 617-23
Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. Gingeras TR, Ghandour G, Wang E, Berno A, Small PM, Drobniewski F, Alland D, Desmond E, Holodniy M, Drenkow J. Genome Res. 1998; 8 (5): 435-48
HIV quantitation in spiked vaginocervical secretions: lack of non-specific inhibitory factors. DATRI 005 Study Team. Division of AIDS Treatment Research Initiative. Holodniy M, Anderson D, Wright D, Sharma O, Cohn J, Alexander N, Stratton P, Reichelderferd P. J Virol Methods. 1998; 72 (2): 185-95
Phenotypic and genotypic testing in clinical practice. Holodniy M, AIDS Patient Care STDS. 1998; 12 (7): 527-31
Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Faculty roundtable discussion. Frost KR, Bellman P, Cohen CJ, Currier J, Dobkin J, El-Sadr W, Holodniy M, Leonard A, Merrick S, Pinsky L, Rubin DS, Saag M, Vaughn A. AIDS Patient Care STDS. 1998; 12 (7): 543-55
Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Question and answer session. Frost KR, Bellman P, Cohen CJ, Currier J, Dobkin J, El-Sadr W, Holodniy M, Leonard A, Merrick S, Pinsky L, Rubin D, Vaughn A, Saag M. AIDS Patient Care STDS. 1998; 12 (7): 557-66
The impact of active herpes simplex virus infection on human immunodeficiency virus load. Mole L, Ripich S, Margolis D, Holodniy M. J Infect Dis. 1997; 176 (3): 766-70
HIV-1 protease inhibitors. A review for clinicians. Deeks SG, Smith M, Holodniy M, Kahn JO. JAMA. 1997; 277 (2): 145-53
Prescribing practice and cost of antibacterial prophylaxis for surgery at a US Veteran Affairs hospital. Ryono RA, Jones KS, Coleman RW, Holodniy M. Pharmacoeconomics. 1996; 10 (6): 630-43
Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. Holodniy M, Katzenstein D, Mole L, Winters M, Merigan T. J Infect Dis. 1996; 174 (4): 854-7
Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay. Kline RL, McNairn D, Holodniy M, Mole L, Margolis D, Blattner W, Quinn TC. J Clin Microbiol. 1996; 34 (11): 2650-3
HIV viral load markers in clinical practice. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. Nat Med. 1996; 2 (6): 625-9
A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. Owens DK, Holodniy M, McDonald TW, Scott J, Sonnad S. JAMA. 1996; 275 (17): 1342-8
Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. Owens DK, Holodniy M, Garber AM, Scott J, Sonnad S, Moses L, Kinosian B, Schwartz JS. Ann Intern Med. 1996; 124 (9): 803-15
Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS. J Infect Dis. 1996; 173 (4): 849-56
Quantitative relationship between platelet count and plasma virion HIV RNA. Holodniy M, Margolis D, Carroll R, Todd J, Mole L. AIDS. 1996; 10 (2): 232-3
HIV viral load quantification, HIV resistance, and antiretroviral therapy. Katzenstein DA, Holodniy M. AIDS Clin Rev. 1995-1996; 277-303
Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S. J Virol. 1995; 69 (6): 3510-6
Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. Todd J, Pachl C, White R, Yeghiazarian T, Johnson P, Taylor B, Holodniy M, Kern D, Hamren S, Chernoff D. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 2 S35-44
Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. Holodniy M, Mole L, Yen-Lieberman B, Margolis D, Starkey C, Carroll R, Spahlinger T, Todd J, Jackson JB. J Clin Microbiol. 1995; 33 (6): 1562-6
Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. Eastman PS, Boyer E, Mole L, Kolberg J, Urdea M, Holodniy M. J Clin Microbiol. 1995; 33 (10): 2777-80
Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. Collier AC, Coombs RW, Katzenstein D, Holodniy M, Gibson J, Mordenti J, Izu AE, Duliege AM, Ammann AJ, Merigan T. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 (2): 150-6
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT. Proc Natl Acad Sci U S A. 1995; 92 (13): 6017-21
Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. Rasmussen L, Morris S, Wolitz R, Dowling A, Fessell J, Holodniy M, Merigan TC. J Infect Dis. 1994; 170 (3): 673-7
The use of pentoxifylline alone in HIV-infected patients. Mole L, Margolis D, Ghotbi L, Holodniy M. J Acquir Immune Defic Syndr. 1994; 7 (5): 519-21
Diurnal and short-term stability of HIV virus load as measured by gene amplification. Holodniy M, Mole L, Winters M, Merigan TC. J Acquir Immune Defic Syndr. 1994; 7 (4): 363-8
Clinical application of reverse transcription-polymerase chain reaction for HIV infection. Holodniy M, Clin Lab Med. 1994; 14 (2): 335-49
Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile. Tsutaoka B, Hansen J, Johnson D, Holodniy M. Clin Infect Dis. 1994; 18 (6): 982-4
Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes. Mole L, Margolis D, Carroll R, Todd J, Holodniy M. J Clin Microbiol. 1994; 32 (9): 2212-5
Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1993; 167 (4): 798-802
Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, Merigan TC. J Acquir Immune Defic Syndr. 1993; 6 (4): 366-9
Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect Montoya, JG, Wood R, Katzenstein D, Holodny M, Merigan TC. Journal of Clinical Microbiology. 1993; 31 (10): 2692-96
Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. Katzenstein DA, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (2): 107-12
Detection and quantification of gene amplification products by a nonisotopic automated system. Holodniy M, Winters MA, Merigan TC. Biotechniques. 1992; 12 (1): 36, 38-9
Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. Clark AG, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (1): 52-9
Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures. Winters MA, Holodniy M, Katzenstein DA, Merigan TC. PCR Methods Appl. 1992; 1 (4): 257-62
Correlation of morphologic diagnosis of Pneumocystis carinii with the presence of pneumocystis DNA amplified by the polymerase chain reaction. Blumenfeld W, McCook O, Holodniy M, Katzenstein DA. Mod Pathol. 1992; 5 (2): 103-6
The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia. Mohle-Boetani J, Akula SK, Holodniy M, Katzenstein D, Garcia G. West J Med. 1992; 156 (3): 303-6
Quantitative virological measures of antiretroviral therapy. Katzenstein DA, Holodniy M. AIDS Clin Rev. 1992; 41-67
Cerebral sparganosis: case report and review. Holodniy M, Almenoff J, Loutit J, Steinberg GK. Rev Infect Dis. 1991 Jan-Feb; 13 (1): 155-9
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, Merigan TC. J Infect Dis. 1991; 163 (4): 862-6
Inhibition of human immunodeficiency virus gene amplification by heparin. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. J Clin Microbiol. 1991; 29 (4): 676-9
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1991; 164 (4): 769-72
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. Holodniy M, Katzenstein DA, Israelski DM, Merigan TC. J Clin Invest. 1991; 88 (5): 1755-9
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. Ann Intern Med. 1990; 112 (4): 247-53
Fulminant Kaposi's sarcoma complicating long-term corticosteroid therapy. Koop HO, Holodniy M, List AF. Am J Med. 1987; 83 (4): 787-9